Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research
Scientists with the UK’s MRC Technology played a key role in humanizing the antibody that would go on to become Keytruda, Merck’s new flagship checkpoint inhibitor. And the windfall of cash that they get in a royalty stream from that effort is financing a makeover and a mission to invest the cash, to fund the ignition of new discovery work aimed at spawning a wave of new biotech product development projects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
